Coherus BioSciences (CHRS) Tops Q2 EPS by 14c, beats revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.55 -0.64%
EPS Growth %: +23.5%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +23.5%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.7 million versus the consensus estimate of $50.47 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- Cal-Maine pays $1.5M in egg price-fixing deal as executives face no charges
- DigitalOcean projects record Q2 2026 results with RPO above $800M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
